Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOKOMEZA - Ebola Disease Therapeutics Trial
PACTR202502676012681Phase 3Not yet recruiting
- Sponsor
- Ministry of Health of Uganda
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Ebola virus disease (EVD) comparing Remdesivir, MBP134 and Remdesivir + MBP134 (3 arms). Primary endpoint: All-cause mortality at 28 days following randomisation. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
remdesivirMBP134
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202502676012681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502676012681.